ONDANSETRON

10 µg/ml oral solution | Therapeutic use: Treatment of coma of myxedema; Management of severe chronic thyroid deficiency and hypothyroid states occurring in the treatment of thyrotoxicosis | ATC: H03AA02 

1, 2, 3, 4, 6, 8 mg/24 h | Therapeutic use: Parkinson’s disease, Restless-Legs-Syndrome | ATC: N04BC09 

1.25 µg (Asthma)/ 2.5 µg (COPD) soft mist inhaler | Therapeutic use: Asthma/ Chronic obstructive pulmonary disease (COPD) | ATC: R03BB04

0.25 mg/ 1 mg powder for concentrate for solution for infusion | Therapeutic use: Advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer | ATC: L01CX01 

100, 200 Mug + 6mcg pressurized metered dose inhaler | Therapeutic use: Asthma maintenance and COPD reliever therapy

50, 100, 150, 200 mg tablets | Therapeutic use: Treatment of partial-onset seizure | ATC: N03AX18

18 Mug capsules dry powder inhaler | Therapeutic use: Chronic obstructive pulmonary disease (COPD) | ATC: R03BB04

37,5 + 325 mg/5ml oral solution | Therapeutic use: Opioid/ Non-opioid pain reliever; moderate to severe pain | ATC: N02AJ13

40 and 80 mg tablets | Therapeutic use: Prostate Cancer | ATC: L02BB04

50 µg + 110 µg capsules dry powder inhaler | Therapeutic use: Chronic obstructive pulmonary disease (COPD) | ATC: R03AL04 

1% - 0.1% cream | Therapeutic use: Skin fungal infections with inflammation | ATC: D01AC20 

150mg film-coated tablets | Therapeutic use: Cystic fibrosis | ATC: R07AX02

List of Pharma Ingredients & Materials Europe.
If you have any question, please contact [email protected]